title: Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats.
abstract: OBJECTIVE
  To investigate any protective effect of early propranolol administration in the development of portal hypertensive gastropathy in cirrhotic rats.
  
  
  METHODS
  For the development of liver cirrhosis and portal hypertensive gastropathy, 60 rats underwent ligation of the left adrenal vein and complete devascularization of the left renal vein, followed by phenobarbital and carbon tetrachloride (CCl(4)) administration. After two weeks of CCl(4) administration, the rats were randomly separated into two groups. In group A, propranolol was continuously administered intragastrically throughout the study, whereas in group B normal saline (placebo) was administered instead. Hemodynamic studies and vascular morphometric analysis of gastric sections were performed after complete induction of cirrhosis.
  
  
  RESULTS
  Vascular morphometric studies showed higher numbers of vessels in all mucosal layers in the control group. Statistical analysis revealed a significantly higher total vascular surface in the control group compared to the propranolol group, but with no statistically significant difference between the mean vascular surfaces between the groups. Our study clearly shows that the increased mucosal blood flow is manifested by a marked increase of vessel count.
  
  
  CONCLUSIONS
  Early propranolol's administration in portal hypertensive cirrhotic rats seems to prevent intense gastric vascular congestion that characterizes portal hypertensive gastropathy.
authors.affiliation: 2nd Propedeutical Department of Surgery, Hippokration General Hospital, Konstantinoupoleos 49, 54630 Thessaloniki, Greece. svrafail@otenet.gr
authors.forename: Savas
authors.initials: S
authors.lastname: Rafailidis
authors.forename: Charalampos
authors.initials: C
authors.lastname: Demertzidis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Ballas
authors.forename: Michail
authors.initials: M
authors.lastname: Alatsakis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Symeonidis
authors.forename: Theodoros
authors.initials: T
authors.lastname: Pavlidis
authors.forename: Kyriakos
authors.initials: K
authors.lastname: Psarras
authors.forename: Valentini
authors.initials: V
authors.lastname: Tzioufa-Asimakopoulou
authors.forename: Athanassios
authors.initials: A
authors.lastname: Sakadamis
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005753:Gastric Mucosa / Q000473:pathology; D006975:Hypertension, Portal / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000150:complications*; D008297:Male; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome
chemical_list: D011433:Propranolol